Skip main navigation

Chimerization and Humanization


Specific mouse mAbs can be routinely generated in large amounts with the use of hybridoma technology. However, mouse mAbs cannot be used for therapy in human due to their immunogenicity. Advances in chimerization and humanization technologies have dramatically improved the performance of mAbs. Recently the use of human antibody-producing transgenic mice and phage display technologies have allowed the development of fully human mAbs.

Chimeric antibodies are made by fusing variable domains from one species, such as a mouse, with constant domains from another species, such as a human being. With such biotechnical manipulation, chimeric antibodies retain the foreign antibody’s antigen specificity and affinity. The development of chimeric and humanized mAbs is facilitated by molecular biology tools like recombinant DNA and fusion technology (not shown here) Note that a fusion protein is a protein consisting of at least two domains that are encoded by separate genes that have been joined as a single unit Structural modifications such as glycosylation and pegylation are introduced herein as formulation factors

This article is from the free online

Pharmacotherapy: Understanding Biotechnology Products

Created by
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now